zanubrutinib


( Last Updated : January 23, 2023)
Generic Name:
zanubrutinib
Project Status:
Received
Therapeutic Area:
Chronic lymphocytic leukemia /small lymphocytic lymphoma.
Manufacturer:
BeiGene Canada ULC
Call for patient/clinician input open:
Brand Name:
Brukinsa
Project Line:
Reimbursement Review
Project Number:
PC0310-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​For the treatment of adult patients with chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openDecember 15, 2022
Call for patient/clinician input closedFebruary 13, 2023
Submission receivedJanuary 20, 2023
Submission acceptedFebruary 06, 2023
Review initiatedFebruary 07, 2023
Draft CADTH review report(s) provided to sponsor for commentApril 25, 2023
Deadline for sponsors commentsMay 05, 2023
CADTH review report(s) and responses to comments provided to sponsorJune 02, 2023
Expert committee meeting (initial)June 14, 2023
Draft recommendation issued to sponsorJune 26, 2023
To
June 28, 2023
Draft recommendation posted for stakeholder feedbackJuly 06, 2023
End of feedback periodJuly 20, 2023